Methocarbamol And Aspirin

Discomfort, Lockjaw, Chronic Pain + 9 more

Treatment

8 FDA approvals

20 Active Studies for Methocarbamol And Aspirin

What is Methocarbamol And Aspirin

Methocarbamol

The Generic name of this drug

Treatment Summary

Methocarbamol is a prescription medicine used to treat muscle spasticity and pain. It comes in tablets, injections, and combination products with other medications, such as acetaminophen, ibuprofen, and codeine. In the United States, it is prescribed as an adjunct to rest and physical therapy for acute musculoskeletal conditions. It was approved by the FDA in 1957. In Canada, lower doses of methocarbamol can be sold over the counter.

Robaxin

is the brand name

Methocarbamol And Aspirin Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Robaxin

Methocarbamol

1959

395

Approved as Treatment by the FDA

Methocarbamol, commonly known as Robaxin, is approved by the FDA for 8 uses including Musculoskeletal Disorders and Muscle Spasms .

Musculoskeletal Disorders

Muscle Spasms

Used to treat Muscle Spasms in combination with Acetaminophen

Pain

Used to treat moderate to severe pain in combination with Acetaminophen

Discomfort

Tetanus

Spasm

Used to treat Muscle Spasms in combination with Acetaminophen

Musculoskeletal Diseases

Lockjaw

Effectiveness

How Methocarbamol And Aspirin Affects Patients

Methacarbamol is a drug that helps relax muscles, although the exact way it works is unknown. Studies have shown that methacarbamol can prevent reflexes from the spinal cord, reduce nerve signals from the spinal cord and brain, and make it harder for muscles to move. When injected, it does not work like a numbing agent. In animal studies, it has been found to help prevent seizures due to electric shock.

How Methocarbamol And Aspirin works in the body

Methocarbamol works by depressing the central nervous system, which has a calming effect on the body. It does this by blocking nerve signals in the spine and brain, and extending the time it takes for muscles to react. It does not affect muscle fibers, nerve fibers, or the motor end plates.

When to interrupt dosage

The advised dosage of Methocarbamol And Aspirin is dependent upon the identified disorder, including Physical Therapy, Gouty Arthritis and Muscle Spasms. The measure additionally changes as indicated by the method of delivery (e.g. Tablet - Oral or Tablet) recorded in the table beneath.

Condition

Dosage

Administration

Physical Therapy

750.0 mg, , 500.0 mg, 100.0 mg/mL, 400.0 mg

Oral, Tablet - Oral, , Tablet, Injection, Injection - Intramuscular; Intravenous, Intramuscular; Intravenous, Tablet, film coated - Oral, Tablet, film coated, Injection, solution, Injection, solution - Intramuscular; Intravenous, Liquid - Intramuscular; Intravenous, Liquid, Tablet, coated, Tablet, coated - Oral, Kit, Injection - Parenteral, Parenteral, Kit - Oral

Lockjaw

750.0 mg, , 500.0 mg, 100.0 mg/mL, 400.0 mg

Oral, Tablet - Oral, , Tablet, Injection, Injection - Intramuscular; Intravenous, Intramuscular; Intravenous, Tablet, film coated - Oral, Tablet, film coated, Injection, solution, Injection, solution - Intramuscular; Intravenous, Liquid - Intramuscular; Intravenous, Liquid, Tablet, coated, Tablet, coated - Oral, Kit, Injection - Parenteral, Parenteral, Kit - Oral

Discomfort

750.0 mg, , 500.0 mg, 100.0 mg/mL, 400.0 mg

Oral, Tablet - Oral, , Tablet, Injection, Injection - Intramuscular; Intravenous, Intramuscular; Intravenous, Tablet, film coated - Oral, Tablet, film coated, Injection, solution, Injection, solution - Intramuscular; Intravenous, Liquid - Intramuscular; Intravenous, Liquid, Tablet, coated, Tablet, coated - Oral, Kit, Injection - Parenteral, Parenteral, Kit - Oral

Chronic Pain

750.0 mg, , 500.0 mg, 100.0 mg/mL, 400.0 mg

Oral, Tablet - Oral, , Tablet, Injection, Injection - Intramuscular; Intravenous, Intramuscular; Intravenous, Tablet, film coated - Oral, Tablet, film coated, Injection, solution, Injection, solution - Intramuscular; Intravenous, Liquid - Intramuscular; Intravenous, Liquid, Tablet, coated, Tablet, coated - Oral, Kit, Injection - Parenteral, Parenteral, Kit - Oral

Muscle Pain

750.0 mg, , 500.0 mg, 100.0 mg/mL, 400.0 mg

Oral, Tablet - Oral, , Tablet, Injection, Injection - Intramuscular; Intravenous, Intramuscular; Intravenous, Tablet, film coated - Oral, Tablet, film coated, Injection, solution, Injection, solution - Intramuscular; Intravenous, Liquid - Intramuscular; Intravenous, Liquid, Tablet, coated, Tablet, coated - Oral, Kit, Injection - Parenteral, Parenteral, Kit - Oral

Rheumatism

750.0 mg, , 500.0 mg, 100.0 mg/mL, 400.0 mg

Oral, Tablet - Oral, , Tablet, Injection, Injection - Intramuscular; Intravenous, Intramuscular; Intravenous, Tablet, film coated - Oral, Tablet, film coated, Injection, solution, Injection, solution - Intramuscular; Intravenous, Liquid - Intramuscular; Intravenous, Liquid, Tablet, coated, Tablet, coated - Oral, Kit, Injection - Parenteral, Parenteral, Kit - Oral

Arthritis, Gouty

750.0 mg, , 500.0 mg, 100.0 mg/mL, 400.0 mg

Oral, Tablet - Oral, , Tablet, Injection, Injection - Intramuscular; Intravenous, Intramuscular; Intravenous, Tablet, film coated - Oral, Tablet, film coated, Injection, solution, Injection, solution - Intramuscular; Intravenous, Liquid - Intramuscular; Intravenous, Liquid, Tablet, coated, Tablet, coated - Oral, Kit, Injection - Parenteral, Parenteral, Kit - Oral

Rest

750.0 mg, , 500.0 mg, 100.0 mg/mL, 400.0 mg

Oral, Tablet - Oral, , Tablet, Injection, Injection - Intramuscular; Intravenous, Intramuscular; Intravenous, Tablet, film coated - Oral, Tablet, film coated, Injection, solution, Injection, solution - Intramuscular; Intravenous, Liquid - Intramuscular; Intravenous, Liquid, Tablet, coated, Tablet, coated - Oral, Kit, Injection - Parenteral, Parenteral, Kit - Oral

Spasm

750.0 mg, , 500.0 mg, 100.0 mg/mL, 400.0 mg

Oral, Tablet - Oral, , Tablet, Injection, Injection - Intramuscular; Intravenous, Intramuscular; Intravenous, Tablet, film coated - Oral, Tablet, film coated, Injection, solution, Injection, solution - Intramuscular; Intravenous, Liquid - Intramuscular; Intravenous, Liquid, Tablet, coated, Tablet, coated - Oral, Kit, Injection - Parenteral, Parenteral, Kit - Oral

Musculoskeletal Diseases

750.0 mg, , 500.0 mg, 100.0 mg/mL, 400.0 mg

Oral, Tablet - Oral, , Tablet, Injection, Injection - Intramuscular; Intravenous, Intramuscular; Intravenous, Tablet, film coated - Oral, Tablet, film coated, Injection, solution, Injection, solution - Intramuscular; Intravenous, Liquid - Intramuscular; Intravenous, Liquid, Tablet, coated, Tablet, coated - Oral, Kit, Injection - Parenteral, Parenteral, Kit - Oral

Inflammation

750.0 mg, , 500.0 mg, 100.0 mg/mL, 400.0 mg

Oral, Tablet - Oral, , Tablet, Injection, Injection - Intramuscular; Intravenous, Intramuscular; Intravenous, Tablet, film coated - Oral, Tablet, film coated, Injection, solution, Injection, solution - Intramuscular; Intravenous, Liquid - Intramuscular; Intravenous, Liquid, Tablet, coated, Tablet, coated - Oral, Kit, Injection - Parenteral, Parenteral, Kit - Oral

Pain

750.0 mg, , 500.0 mg, 100.0 mg/mL, 400.0 mg

Oral, Tablet - Oral, , Tablet, Injection, Injection - Intramuscular; Intravenous, Intramuscular; Intravenous, Tablet, film coated - Oral, Tablet, film coated, Injection, solution, Injection, solution - Intramuscular; Intravenous, Liquid - Intramuscular; Intravenous, Liquid, Tablet, coated, Tablet, coated - Oral, Kit, Injection - Parenteral, Parenteral, Kit - Oral

Warnings

Methocarbamol And Aspirin has one contraindication. It should not be administered when encountering the conditions found in the following table.

Methocarbamol And Aspirin Contraindications

Condition

Risk Level

Notes

Severe Hypersensitivity Reactions

Do Not Combine

Methocarbamol may interact with Pulse Frequency

There are 20 known major drug interactions with Methocarbamol And Aspirin.

Common Methocarbamol And Aspirin Drug Interactions

Drug Name

Risk Level

Description

Azelastine

Major

Methocarbamol may increase the central nervous system depressant (CNS depressant) activities of Azelastine.

Ethanol

Major

Methocarbamol may increase the central nervous system depressant (CNS depressant) activities of Ethanol.

Oliceridine

Major

The risk or severity of hypotension, sedation, death, somnolence, and respiratory depression can be increased when Methocarbamol is combined with Oliceridine.

Thalidomide

Major

Methocarbamol may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.

Daridorexant

Minor

The risk or severity of CNS depression can be increased when Methocarbamol is combined with Daridorexant.

Methocarbamol And Aspirin Toxicity & Overdose Risk

Overdosing on methocarbamol can cause nausea, drowsiness, vision problems, low blood pressure, seizures, and unconsciousness. Treatment for overdose typically consists of maintaining the patient's airways, monitoring vital signs, and giving fluids intravenously if needed. The toxic dose for rats is 3576.2mg/kg. Pregnant and nursing women should be cautious when taking methocarbamol, as it is classified as pregnancy category C and is excreted in the milk of dogs. No studies have been done to assess the effects of methocarbamol on fertility, mutagenicity, or

Methocarbamol And Aspirin Novel Uses: Which Conditions Have a Clinical Trial Featuring Methocarbamol And Aspirin?

At present, 356 active clinical trials are being conducted to investigate the potential of Methocarbamol and Aspirin in providing relief for Gouty Arthritis, Rest and Musculoskeletal Diseases.

Condition

Clinical Trials

Trial Phases

Physical Therapy

6 Actively Recruiting

Not Applicable

Musculoskeletal Diseases

2 Actively Recruiting

Not Applicable, Phase 2, Phase 3

Chronic Pain

130 Actively Recruiting

Not Applicable, Phase 4, Phase 2, Phase 3, Early Phase 1, Phase 1

Inflammation

0 Actively Recruiting

Lockjaw

0 Actively Recruiting

Rheumatism

0 Actively Recruiting

Rest

0 Actively Recruiting

Spasm

0 Actively Recruiting

Discomfort

0 Actively Recruiting

Arthritis, Gouty

0 Actively Recruiting

Pain

0 Actively Recruiting

Muscle Pain

3 Actively Recruiting

Phase 4, Not Applicable, Phase 2

Patient Q&A Section about methocarbamol and aspirin

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Can you take muscle relaxers and aspirin together?

"This does not necessarily mean no interactions exist. Always consult your healthcare provider.

There are no known interactions between Aspirin Low Strength and cyclobenzaprine, but this does not mean that no interactions exist. Always consult your healthcare provider."

Answered by AI

How much aspirin is in methocarbamol?

"Methocarbamol and Aspirin tablets, for oral administration, each containing: Methocarbamol, USP 400 mg - Aspirin, USP 325 mg. Inactive Ingredients: Pregelatinized starch, povidone, croscarmellose sodium."

Answered by AI

Does methocarbamol 750 mg have aspirin in it?

"This drug contains aspirin. However, children and teenagers less than 18 years old should not take aspirin if they have chickenpox, flu, or any undiagnosed illness or if they have recently received a vaccine. In these cases, taking aspirin increases the risk of Reye's syndrome, a rare but serious illness."

Answered by AI

What can you not take with methocarbamol?

"The following drugs can help reduce anxiety: lorazepam, diazepam, clonazepam, and alprazolam. Pain drugs such as oxycodone, hydrocodone, tramadol, and morphine can also help reduce anxiety. Certain antidepressants, such as amitriptyline, doxepin, and imipramine, can also help reduce anxiety."

Answered by AI

Clinical Trials for Methocarbamol And Aspirin

Image of Cedars Sinai Medical Offices East Tower in Los Angeles, United States.

Active VR for Anxiety During ENT Procedures

18+
All Sexes
Los Angeles, CA

The purpose of this research is to evaluate whether active virtual reality reduces pain and anxiety more effectively than passive virtual reality during office-based ENT procedures. The main procedures include exposure to virtual reality (passive calming scenery or interactive puzzle game) via Paperplane Therapeutics software with VR headset or glasses during common in-office ENT procedures, participant self-report surveys (GAD-7, PHQ-9, PEG, VAS, SUDS, Likert, experience questions), and physician post-procedure survey. The study will enroll individuals 18 years or older who are scheduled to undergo common office-based ENT procedures (turbinate reduction, nasal debridement, balloon sinuplasty, radiofrequency ablation, nasal polypectomy, eustachian tube dilation, vocal fold injection, or subglottic steroid injection) at Cedars Sinai.

Waitlist Available
Has No Placebo

Cedars Sinai Medical Offices East Tower

Image of UCI Health Susan Samueli Integrative Health Institute in Irvine, United States.

Biofield Therapy for Cancer

18+
All Sexes
Irvine, CA

Cancer treatment with immunotherapy is often associated with symptoms such as fatigue, pain, and emotional distress, which may affect patients' daily functioning and quality of life. Additional supportive care approaches are being studied to better understand their potential role in supporting these symptoms. The purpose of this study is to learn whether a biofield therapy, called Reiki may help to support adults with cancer who are receiving immunotherapy and currently struggling with fatigue. Reiki is a non-invasive complementary therapy delivered by a trained practitioner who places their hands lightly near the body. It is intended to promote relaxation and support general well-being. Reiki is used as a supportive practice and is not considered a medical treatment or replacement for standard care. The secondary goal of this study is to evaluate the feasibility of delivering Reiki in this clinical setting. This includes examining recruitment, retention, adherence to study procedures, and overall participant engagement. Lastly, the third aim is to explore participants' experiences with Reiki through guided interviews. Participants enrolled in this study will first be asked to participate in a one-hour, one-on-one interview about their experiences with cancer treatment, their symptoms, and their thoughts about integrative care practices such as Reiki. After the interview, they will be randomly assigned to one of two groups: Immediate Reiki Group: If participants are assigned to this group, they will receive six weekly, in-person 30-minute Usui Reiki sessions from a Reiki master at the Susan Samueli Integrative Health Institute. Before and after each session, participants will complete questionnaires about fatigue, pain, and stress. At the first and final sessions, a small blood sample will be collected to measure inflammatory biomarkers, and Electroencephalogram (EEG) hyperscanning will be conducted to measure brain activity and connectivity between the participant and the practitioner. Four weeks after the final session, they will complete the questionnaires again, followed by a short satisfaction survey about their experience. Waitlist Group: If they are assigned to the waitlist group, they will first complete a 6-week observation period that includes brief weekly fatigue questionnaires and two in-person 30-minute sessions with EEG measurements at Week 1 and Week 6. This will be followed by a 4-week period with no sessions, after which they will complete questionnaires about fatigue, pain, and psychological distress. Participants will then begin the same six weekly, in-person 30-minute sessions described above. As with the Immediate Group, they will complete questionnaires before and after each session. At the first and final sessions, a small blood sample will be collected and EEG hyperscanning will be conducted. At the end of the study, participants will also complete a short satisfaction survey about their experience. The investigators hypothesize that participants receiving Reiki will report improvements in symptoms and well-being compared to those not yet receiving Reiki, and that the intervention will be feasible to implement and acceptable to participants.

Recruiting
Has No Placebo

UCI Health Susan Samueli Integrative Health Institute (+1 Sites)

Image of Alberta Children's Hospital in Calgary, Canada.

Therapeutic Cuddling for Pain in Critically Ill Children

< 65
All Sexes
Calgary, Canada

2.1 CONTEXT Pain and agitation are common comorbidities of pediatric critical illness due to both underlying disease processes and ICU related therapies. These are associated with both short and long term negative sequelae including increased mortality, length of stay, rates of ICU delirium, worse sleep, increased anxiety, depression, and chronic pain. The current standard of care to manage PICU associated pain and agitation is the use of analgosedation (e.g. opioids and benzodiazepines) these too are associated with increased time on the ventilator, length of stay, ICU delirium, and long term mental health and negative neuro-cognitive outcomes. Despite recommendations for increased use of non-pharmacologic therapies in the prevention and management of PICU associated pain, agitation, delirium, and analgosedation exposure, there are currently know therapies with clear evidence of efficacy. Therapeutic cuddling (e.g. kangaroo care, clothed cuddling, comfort holding, etc.) has been shown to decrease pain and anxiety in critically ill neonates, and healthy children and adults. Positive affective touch and hugging has known physiologic benefits and has been associated with decreased pain, improved immunity, and decreased mortality. Despite the potential for this intervention to aid in the prevention and management of PICU associated pain, agitation, delirium and analgosedation exposure, little data exists on efficacy of therapeutic cuddling in critically ill children. 2.2 OBJECTIVES 2.2.1 Primary Determine the feasibility of screening, consent, randomization, and retention of participants in a pragmatic RCT of therapeutic cuddling versus standard of care in the Alberta Children's Hospital Pediatric Intensive Care Unit. 2.2.2 Secondary 1. Determine treatment fidelity of participants randomized to the intervention arm. 2. Determine the prevalence of the therapeutic cuddling intervention in those randomized to the standard of care arm. 3. Determine the feasibility of measurement of key outcomes and co-variates (i.e., pain, agitation, sedation, delirium, analgosedation exposure, parental presence). 4. Describe the experience of patients, caregivers, and healthcare professionals in delivering/receiving the therapeutic cuddling intervention. 2.3 STUDY DESIGN Pilot feasibility randomized controlled trial of a structured co-designed therapeutic cuddling intervention as compared to the standard of care in a single tertiary care PICU. 2.4 DURATION 6 months to 1 year 2.5 LOCATION, DEPARTMENTS, AND FACILITY WHERE RESEARCH WILL BE UNDERTAKEN The pediatric intensive care unit at the Alberta Children's Hospital 2.6 SAMPLE SIZE A total sample size of 112 participants (56 per arm)

Recruiting
Has No Placebo

Alberta Children's Hospital

Have you considered Methocarbamol And Aspirin clinical trials?

We made a collection of clinical trials featuring Methocarbamol And Aspirin, we think they might fit your search criteria.
Go to Trials
Image of Marquette University in Milwaukee, United States.

Exercise for Pain

35 - 65
All Sexes
Milwaukee, WI

The goal of this clinical trial is to determine how male and female former athletes experience pain and respond to moderate-intensity exercise (strength versus aerobic) compared with both current master's athletes and nonathletes. The main questions this study aims to address are: 1. How do former athletes, master's athletes, and nonathletes experience pain? 2. How do different types of moderate-intensity exercise (strength versus aerobic exercise) influence pain in former athletes, master's athletes, and nonathletes? Participants will complete 3 different testing sessions: 1. Baseline testing including assessments of strength, cardiorespiratory fitness, and pain; 2. Strength exercise: pain assessments will occur before and after moderate-intensity strength training exercise; 3. Aerobic exercise: pain assessments will occur before and after moderate-intensity aerobic exercise. There will be a washout period of approximately one week or greater between each of the three different testing sessions. The order of conditions (strength versus aerobic exercise) will be randomized (crossover randomized trial design).

Recruiting
Has No Placebo

Marquette University

Jacob J Capin, DPT, PhD

Have you considered Methocarbamol And Aspirin clinical trials?

We made a collection of clinical trials featuring Methocarbamol And Aspirin, we think they might fit your search criteria.
Go to Trials
Image of Donald Berman Maimonides Maimonides Geriatric Centre in Montreal, Canada.

Virtual Reality for Pain

Any Age
All Sexes
Montreal, Canada

This study will test whether immersive virtual reality (iVR) can reduce pain and discomfort during wound care for residents living in long-term care (LTC). Pressure ulcers are common and painful among older adults, and dressing changes often cause additional distress. Up to 20 residents at the Donald Berman Maimonides Geriatric Centre will use virtual reality headsets during routine wound care. The headsets display calm, low-stimulus scenes (e.g., puppies in a meadow) designed to distract and comfort participants. Each participant will take part for six weeks in three phases: * Two weeks of usual wound care (baseline) * Two weeks using virtual reality during wound care (intervention) * Two weeks of usual care again (washout) Pain will be assessed using validated tools, and the research team will also observe agitation, mood, and other behavioral indicators. Nursing staff will provide feedback on feasibility and acceptability of iVR use in LTC settings.

Recruiting
Has No Placebo

Donald Berman Maimonides Maimonides Geriatric Centre

Machelle Wilchesky, PhD

Image of Cincinnati Urogynecology Associates in Cincinnati, United States.

Nitrous Oxide for Pain During Bladder Botox Injections

18+
Female
Cincinnati, OH

The goal of this clinical trial is to assess if a mix of nitrous oxide and oxygen can improve pain control during bladder Botox injections. The primary question it aims to answer is: Does using nitrous oxide lower the overall level of pain during the procedure? Researchers will compare a 50:50 nitrous oxide/oxygen mixture (administered with the Pro-Nox system) plus standard care (with lidocaine in the bladder) to sham mask plus standard care to see if nitrous oxide works better for lowering pain. Participants will: * Receive their bladder Botox injection in the office setting * Either use nitrous oxide/oxygen plus standard care during the procedure, or sham mask plus standard care * Answer brief questions about pain, anxiety, satisfaction, and willingness to repeat the procedure

Phase 4
Waitlist Available

Cincinnati Urogynecology Associates (+1 Sites)

Have you considered Methocarbamol And Aspirin clinical trials?

We made a collection of clinical trials featuring Methocarbamol And Aspirin, we think they might fit your search criteria.
Go to Trials